Verve Therapeutics Inc (VERV)
13.19
+0.40
(+3.13%)
USD |
NASDAQ |
Mar 27, 16:00
13.20
+0.01
(+0.08%)
After-Hours: 20:00
Verve Therapeutics Cash from Financing (Quarterly): 177.38M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 177.38M |
September 30, 2023 | 31.92M |
June 30, 2023 | 1.233M |
March 31, 2023 | 2.038M |
December 31, 2022 | 39.60M |
September 30, 2022 | 288.41M |
June 30, 2022 | 0.445M |
March 31, 2022 | 0.505M |
Date | Value |
---|---|
December 31, 2021 | 1.224M |
September 30, 2021 | -0.867M |
June 30, 2021 | 282.90M |
March 31, 2021 | 93.83M |
December 31, 2020 | 0.008M |
September 30, 2020 | 0.00 |
June 30, 2020 | 62.89M |
March 31, 2020 | 29.73M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.867M
Minimum
Sep 2021
288.41M
Maximum
Sep 2022
63.20M
Average
15.88M
Median
Cash from Financing (Quarterly) Benchmarks
Intellia Therapeutics Inc | 106.48M |
Beam Therapeutics Inc | 33.71M |
Editas Medicine Inc | 0.514M |
Moderna Inc | -109.00M |
Ionis Pharmaceuticals Inc | 40.72M |
Cash from Financing (Quarterly) Related Metrics
Cash from Operations (Quarterly) | -40.68M |
Cash from Investing (Quarterly) | -8.893M |
Free Cash Flow | -158.83M |
Free Cash Flow Per Share (Quarterly) | -0.5229 |
Free Cash Flow to Equity (Quarterly) | -42.86M |
Free Cash Flow to Firm (Quarterly) | -42.86M |
Free Cash Flow Yield | -17.91% |